<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="109355">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02024464</url>
  </required_header>
  <id_info>
    <org_study_id>CP-10-002</org_study_id>
    <nct_id>NCT02024464</nct_id>
  </id_info>
  <brief_title>Compare the Hydrus Microstent(TM) to the iStent for Lowering IOP in Glaucoma Patients Having Cataract Surgery (Hydrus III)</brief_title>
  <acronym>Hydrus III</acronym>
  <official_title>A Prospective, Multicenter, Randomized Comparison of the Hydrus Microstent to the iStent for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ivantis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ivantis, Inc.</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <authority>Austria: Austrian Medicines and Medical Devices Agency</authority>
    <authority>Italy: Ministry of Health</authority>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <authority>Poland: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial compares two implantable devices intended to lower the pressure inside
      the eye of glaucoma patients.  One of the two devices will be implanted immediately
      following cataract surgery and the placement of a posterior chamber intra-ocular lens.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter, single-masked, randomized clinical trial comparing
      Cataract Extraction (CE) + Hydrus Microstent to CE surgery + iStent implant for the
      reduction of intraocular pressure in patients with a positive diagnosis of primary open
      angle glaucoma, pseudoexfoliative glaucoma, or pigmentary dispersion glaucoma with an
      operable cataract.  Eligible patients will be scheduled for cataract surgery.  At the
      conclusion of successful cataract surgery and the placement of a posterior-chamber IOL,
      qualified subjects will be randomized to receive either the Hydrus Microstent or the iStent
      implant.  Post-operative follow-up visits will be conducted at regular intervals.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Intraocular pressure at Month 12</measure>
    <time_frame>Twelve months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary effectiveness endpoint for this study is IOP at 12 months following surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients requiring supplemental medication.</measure>
    <time_frame>Month 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>The proportion of patients requiring supplemental medication for pressure control.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Proportion of eyes with IOP greater than 5 and less than or equal to 19 mmHg.</measure>
    <time_frame>Month 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>The proportion of eyes with IOP greater than 5 and less than or equal to 19 mmHg at 12  months after surgery.</description>
  </other_outcome>
  <other_outcome>
    <measure>Loss of best-corrected visual acuity (BCVA)</measure>
    <time_frame>Month 12</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety outcomes include loss of lines of BCVA, results of slit lamp and fundus examination, and the incidence of complications and adverse events.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <condition>Pseudoexfoliative Glaucoma</condition>
  <condition>Pigmentary Dispersion Glaucoma</condition>
  <arm_group>
    <arm_group_label>Hydrus Microstent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to the Hydrus Microstent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>iStent Trabecular Micro Bypass</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to the iStent Trabecular Micro Bypass</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hydrus Microstent</intervention_name>
    <description>Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.</description>
    <arm_group_label>Hydrus Microstent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iStent Trabecular Micro Bypass</intervention_name>
    <description>Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.</description>
    <arm_group_label>iStent Trabecular Micro Bypass</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A diagnosis of primary open angle glaucoma (POAG), Pseudoexfoliative (PXG) glaucoma,
             or Pigmentary dispersion glaucoma (PDG)

          -  An operable age-related cataract with BCVA of 20/40 or worse, eligible for
             phacoemulsification.

        Exclusion Criteria:

          -  Forms of primary or secondary glaucoma not listed above

          -  Prior glaucoma surgery in the study eye
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iqbal K. Ahmed, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mississauga, ON, Canada</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brett Trauthen</last_name>
    <phone>949/333-1315</phone>
    <email>btrauthen@ivantisinc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paul Rhee, OD</last_name>
    <phone>949/333-1316</phone>
    <email>prhee@ivantisinc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Contact Brett Trauthen at Ivantis</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92618</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 27, 2013</lastchanged_date>
  <firstreceived_date>December 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary open angle glaucoma</keyword>
  <keyword>POAG</keyword>
  <keyword>Pseudoexfoliative glaucoma</keyword>
  <keyword>PXG</keyword>
  <keyword>Pigmentary dispersion glaucoma</keyword>
  <keyword>PDG</keyword>
  <keyword>Hydrus</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
